How to Get Crestor (Rosuvastatin) in Tennessee

Who Can Prescribe Rosuvastatin in Tennessee

Any licensed prescriber in the state with authority to write Schedule VI or legend drug prescriptions can prescribe rosuvastatin. That includes MDs, DOs, nurse practitioners, and physician assistants.

Tennessee's APRN Practice Act (TCA § 63-7-123) grants nurse practitioners independent prescriptive authority for non-controlled legend drugs, which includes all statins. A 2025 revision removed the prior requirement for a collaborative agreement for NPs with more than 4 to 000 hours of clinical practice. PAs still require a supervising physician relationship but can prescribe rosuvastatin without a separate DEA number since it is not a controlled substance. Practically, this means patients in rural parts of the state (where physician density is lower) can receive a rosuvastatin prescription from a local NP-run clinic without a physician co-signature.

Getting Rosuvastatin Through Telehealth in Tennessee

Tennessee allows telehealth prescribing of rosuvastatin. An initial audio-video visit satisfies the prescriber-patient relationship requirement, and refills can be managed via asynchronous messaging in most platforms.

The Tennessee Board of Medical Examiners adopted permanent telehealth rules in 2023 that carried forward pandemic-era flexibilities for non-controlled medications. A prescriber licensed in Tennessee (or holding an active Interstate Medical Licensure Compact credential) can evaluate a patient's cardiovascular risk, review uploaded labs, and electronically prescribe rosuvastatin to any Tennessee pharmacy. The 2018 AHA/ACC Cholesterol Guideline recommends shared decision-making around statin initiation, which telehealth visits can accommodate through screen-shared risk calculators and lab review. Several national telehealth platforms, including HealthRX, operate in Tennessee and can send a prescription to the patient's preferred local or mail-order pharmacy the same day as the visit.

Patients should have recent labs (drawn within the prior 90 days) available at the time of the visit. If labs are older or unavailable, the telehealth provider will order them through a Tennessee-licensed laboratory network such as Quest or Labcorp, both of which maintain draw sites in all major Tennessee metro areas and many rural counties.

Required Labs Before Starting Rosuvastatin

A fasting lipid panel and hepatic function panel (ALT, AST) are the minimum lab work before a first rosuvastatin prescription. The FDA label also recommends checking creatine kinase if a patient reports unexplained muscle pain.

The rosuvastatin prescribing information specifies hepatic transaminase measurement before initiation and "as clinically indicated thereafter." The 2018 AHA/ACC guideline recommends a baseline fasting lipid panel to calculate 10-year ASCVD risk using the Pooled Cohort Equations and to establish a pre-treatment LDL-C level [1]. For patients aged 40 to 75 with LDL-C between 70 and 189 mg/dL, a 10-year ASCVD risk of 7.5% or higher triggers a moderate- to high-intensity statin recommendation [1].

In Tennessee, most commercial insurers and employer plans accept labs drawn at any CLIA-certified facility. TennCare members can use state-contracted labs without an out-of-pocket cost. Typical turnaround time for a standard lipid panel in Tennessee is 24 to 48 hours from a morning fasting draw.

Additional labs that some prescribers order (but that are not universally required) include:

• HbA1c to screen for diabetes risk, since rosuvastatin carries a small increase in new-onset diabetes incidence. In the JUPITER trial (N=17,802), rosuvastatin 20 mg increased physician-reported diabetes by 0.6 percentage points versus placebo over a median 1.9 years of follow-up [2].
• Thyroid-stimulating hormone (TSH) if secondary causes of hyperlipidemia are suspected.
• Renal function (eGFR) because the 40 mg dose is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) per the FDA label.

Tennessee Pharmacy Access and Pricing

Generic rosuvastatin is stocked at virtually every retail pharmacy in Tennessee, including CVS, Walgreens, Walmart, Kroger, and independent pharmacies. Cash prices for a 30-day supply typically range from $8 to $25 depending on dose and retailer.

Since AstraZeneca's Crestor patent expired in 2016 and multiple generic manufacturers entered the market, prices have dropped sharply. Brand-name Crestor remains available but costs $300 to $400 per month without insurance. Few clinical scenarios require the brand product. The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) rates all approved rosuvastatin generics as "AB" rated, meaning they are fully substitutable.

For patients seeking the lowest out-of-pocket cost:

• Walmart and Kroger in Tennessee carry rosuvastatin on their $4/$10 generic lists (30-day and 90-day supply, respectively) for the 5 mg and 10 mg strengths.
• Cost Plus Drugs (Mark Cuban) ships to Tennessee addresses and lists rosuvastatin at $4.20 for a 30-day supply of 10 mg plus a flat dispensing fee.
• GoodRx and RxSaver coupons regularly bring the price below $12 at Tennessee CVS and Walgreens locations for all strengths including 20 mg and 40 mg.

503A Compounding Pharmacies in Tennessee

Tennessee-licensed 503A compounding pharmacies can prepare rosuvastatin formulations and ship them to patients within the state. This is most relevant for patients who need a non-standard dose form, such as a suspension for dysphagia.

Under Tennessee's Board of Pharmacy rules (Tenn. Comp. R. & Regs. 1140-01) and federal law (FDCA § 503A), a 503A pharmacy compounds patient-specific prescriptions from bulk or finished-product API. Because generic rosuvastatin tablets are widely available and inexpensive, compounding is rarely needed for cost reasons alone. The primary use case is a patient who cannot swallow tablets (post-stroke dysphagia, pediatric familial hypercholesterolemia) and needs an oral suspension. A valid, patient-specific prescription from a Tennessee-licensed prescriber is required.

TennCare Coverage and Prior Authorization

TennCare (Tennessee Medicaid) does not cover rosuvastatin for standard hyperlipidemia or ASCVD primary prevention. Coverage is limited to patients with a type 2 diabetes diagnosis. Patients without a T2D diagnosis who are on TennCare will need to appeal or use an alternative statin.

This coverage gap is significant. The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced major cardiovascular events by 44% (HR 0.56 to 95% CI 0.46 to 0.69, P<0.00001) in patients with elevated hsCRP but LDL-C below 130 mg/dL, a population that does not carry a diabetes diagnosis by default [2]. Dr. Paul Ridker, the trial's principal investigator, stated: "These data provide evidence that statin therapy may have benefits among individuals who are not currently candidates for statin treatment on the basis of existing guidelines."

For TennCare members who do carry a T2D diagnosis, rosuvastatin requires a prior authorization. The documentation the managed care organization (MCO) typically requests includes:

• Documented diagnosis of type 2 diabetes (ICD-10 E11.x)
• Recent fasting lipid panel showing LDL-C above the treatment threshold
• Documentation that at least one preferred formulary statin (usually atorvastatin or simvastatin) was tried and either failed to reach goal LDL-C or caused intolerable side effects
• Prescriber's clinical rationale for rosuvastatin specifically

Tennessee's three TennCare MCOs (BlueCare, Amerigroup, and UnitedHealthcare Community Plan) each process PAs within 24 to 72 hours for standard requests. Urgent requests receive a response within 24 hours.

Commercial Insurance Coverage in Tennessee

Most commercial insurers in Tennessee cover generic rosuvastatin on Tier 1 (preferred generic) without prior authorization. Brand Crestor, if prescribed, typically falls on Tier 3 or requires step therapy through generic rosuvastatin first.

The 2019 ACC/AHA Primary Prevention Guideline classifies rosuvastatin 20 to 40 mg as high-intensity statin therapy, expected to lower LDL-C by 50% or more [3]. This guideline endorsement helps support medical necessity when a prior authorization is triggered, though it is rarely needed for the generic product. Tennessee's largest commercial plans (BCBS of Tennessee, Cigna, and UnitedHealthcare) all list generic rosuvastatin as a preferred formulary drug.

Patients with high-deductible health plans may still pay cash price until their deductible is met. In that scenario, the generic pricing strategies described above (Walmart $4 list, GoodRx coupons) apply equally to commercially insured patients.

Transferring a Crestor Prescription to Tennessee

Patients moving to Tennessee from another state can transfer an existing rosuvastatin prescription to a Tennessee pharmacy. Tennessee Board of Pharmacy rules permit inter-state prescription transfers for non-controlled legend drugs.

The process is straightforward. The patient contacts a Tennessee pharmacy and provides the name and phone number of the originating pharmacy. The receiving pharmacist calls the transferring pharmacist, verifies the prescription details and remaining refills, and enters the prescription into the Tennessee pharmacy's system. Electronic prescription records in systems like Surescripts make this faster. The entire transfer typically takes under one business day. If the original prescription has no remaining refills, the Tennessee pharmacist can contact the prescriber (even an out-of-state prescriber) for a new authorization, or the patient can establish care with a Tennessee prescriber or telehealth provider.

Patients who used a mail-order pharmacy in their previous state can also switch to a Tennessee-based mail-order option or continue using a nationally licensed mail-order pharmacy, as long as the prescriber writes a new prescription or the existing one has refills remaining.

Rosuvastatin Dosing and Clinical Monitoring

Most adults in Tennessee starting rosuvastatin for primary prevention begin at 10 mg or 20 mg once daily, taken at any time of day with or without food. The dose may be titrated based on LDL-C response at 4 to 12 weeks.

The 2018 AHA/ACC Cholesterol Guideline stratifies statin intensity as follows for rosuvastatin [1]:

• Moderate intensity (30% to 49% LDL-C reduction): 5 mg to 10 mg daily
• High intensity (≥50% LDL-C reduction): 20 mg to 40 mg daily

A follow-up lipid panel is recommended 4 to 12 weeks after initiation or dose adjustment, and then every 3 to 12 months to confirm adherence and therapeutic response. Liver enzymes do not require routine serial monitoring per the 2012 FDA label update, but should be rechecked if symptoms of hepatotoxicity develop (fatigue, anorexia, jaundice, dark urine).

The JUPITER trial found that rosuvastatin 20 mg reduced LDL-C by a median of 50% and hsCRP by 37% over 1.9 years [2]. Patients of Asian descent may have higher rosuvastatin exposure at any given dose; the FDA label recommends starting at 5 mg in this population.

Dr. Neil Stone, chair of the 2013 ACC/AHA guideline panel, noted: "Rosuvastatin at 20 mg is the most potent single-agent statin available for patients who need aggressive LDL lowering without combination therapy."

Timeline From Visit to First Dose

For most Tennessee patients, the timeline from initial telehealth visit to taking the first rosuvastatin dose is 1 to 3 days if recent labs are available, or 5 to 7 days if new labs need to be drawn.

Here is a typical sequence:

1. Day 0: Patient uploads existing labs (or orders new labs through the telehealth platform). In Tennessee, Quest Diagnostics and Labcorp each operate 50+ draw sites.
2. Day 1 to 2: Lab results returned. Prescriber reviews lipid panel and liver enzymes, calculates 10-year ASCVD risk, and sends electronic prescription to the patient's chosen pharmacy.
3. Day 2 to 3: Tennessee pharmacy fills the prescription. Most retail pharmacies stock generic rosuvastatin and can fill same-day.
4. Day 3 (or sooner): Patient picks up medication or receives mail-order shipment.

If prior authorization is required (TennCare or certain commercial plans), add 1 to 3 business days. Patients can ask their prescriber to submit a PA appeal to the MCO citing guideline-concordant therapy if the initial request is denied.